{
    "clinical_study": {
        "@rank": "35035", 
        "acronym": "TOPplus-IgAN", 
        "arm_group": [
            {
                "arm_group_label": "prednisone plus cyclophosphamide", 
                "arm_group_type": "Experimental", 
                "description": "prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)"
            }, 
            {
                "arm_group_label": "prednisone alone", 
                "arm_group_type": "Experimental", 
                "description": "prednisone alone: prednisone(0.5mg/kg/day*6 months)"
            }
        ], 
        "brief_summary": {
            "textblock": "Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone\n      alone in patients with advanced-stage IgA nephropathy."
        }, 
        "brief_title": "Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "IgA Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  biopsy-proven primary IgA nephropathy;\n\n          -  18-70 years old;\n\n          -  serum Creatinine:1.5-3.0mg/dl;\n\n          -  with a written consent from participants to receive prednisone and/or\n             cyclophosphamide\n\n        Exclusion Criteria:\n\n          -  diabetes;\n\n          -  contraindications for the treatment of prednisone and/or cyclophosphamide;\n\n          -  any treatment with steroids or immunosuppressive drugs prior to this study;\n\n          -  acute deterioration of renal function(including those of glomerular origin)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758120", 
            "org_study_id": "GGH2012-36", 
            "secondary_id": "GGH2012-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "prednisone plus cyclophosphamide", 
                "description": "prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)", 
                "intervention_name": "prednisone plus cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "prednisone alone", 
                "description": "prednisone alone: prednisone(0.5mg/kg/day*6 months)", 
                "intervention_name": "Prednisone alone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IgA nephropathy", 
            "Cyclophosphamide", 
            "prednisone"
        ], 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "contact": {
                "email": "zhangbinyes@yahoo.com.cn", 
                "last_name": "Bin Zhang, MD PhD", 
                "phone": "+86-13925056339"
            }, 
            "contact_backup": {
                "email": "13828431229@139.com", 
                "last_name": "Zhongling Feng, Master", 
                "phone": "+86-13828431229"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510080"
                }, 
                "name": "Guangdong General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Bin Zhang, MD PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "zhongling Feng, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jianteng Xie, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Huaban Liang, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lixia Xu, MD  PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy", 
        "other_outcome": {
            "description": "Number of Participants with Adverse Events; adverse events include hair loss, vomiting, diarrhea, jaundice, leukopenia, anemia, thrombocytopenia, infections, allergic reactions and hemorrhagic cystitis.", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "1,3,6 ,12, 24 and 36 months or more after treatment"
        }, 
        "overall_contact": {
            "email": "weishi_gz@126.com", 
            "last_name": "Wei Shi, MD, PhD", 
            "phone": "(86-20)83850849"
        }, 
        "overall_official": {
            "affiliation": "Guangdong General Hospital", 
            "last_name": "wei shi, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the changes of glomerular filtration rate (GFR) or a combination of reaching end-stage renal disease (ESRD) or doubling of serum Creatinine", 
            "measure": "the changes of kidney function", 
            "safety_issue": "Yes", 
            "time_frame": "3,6 ,12, 24 and 36 months or more after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758120"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangdong General Hospital", 
            "investigator_full_name": "Wei Shi", 
            "investigator_title": "Prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "the changes of proteinuria", 
            "safety_issue": "Yes", 
            "time_frame": "3,6 ,12, 24 and 36 months or more after treatment"
        }, 
        "source": "Guangdong General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}